Pathogenesis and Novel Therapeutics in Asthma
Asthma is a prevalent chronic inflammatory disease of the airways with complex etiology and mechanistic pathways and variable clinical presentation. Such heterogeneity renders the search for targeted therapies difficult. Currently, the best-known disease phenotype with tailored biological treatment...
Format: | eBook |
---|---|
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
LEADER | 04149namaa2200997uu 4500 | ||
---|---|---|---|
001 | doab101322 | ||
003 | oapen | ||
005 | 20230714 | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 230714s2023 xx |||||o ||| 0|eng d | ||
020 | |a 9783036578422 | ||
020 | |a 9783036578439 | ||
020 | |a books978-3-0365-7843-9 | ||
024 | 7 | |a 10.3390/books978-3-0365-7843-9 |2 doi | |
040 | |a oapen |c oapen | ||
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
720 | 1 | |a Bazan-Socha, Stanislawa |4 edt | |
720 | 1 | |a Bazan-Socha, Stanislawa |4 oth | |
245 | 0 | 0 | |a Pathogenesis and Novel Therapeutics in Asthma |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 online resource (168 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
520 | |a Asthma is a prevalent chronic inflammatory disease of the airways with complex etiology and mechanistic pathways and variable clinical presentation. Such heterogeneity renders the search for targeted therapies difficult. Currently, the best-known disease phenotype with tailored biological treatment is eosinophilic asthma; however, even in some of these patients, anti-IL5 treatment is ineffective. Furthermore, about a quarter of patients, especially those with a severe phenotype, develop progressive and irreversible airway obstruction, leading to persistent symptoms despite optimized treatment. Therefore, new therapeutic approaches are still needed, particularly in severe asthma. The Special Issue presents asthma research focusing on modern personalized therapeutic approaches. Particular interest is directed to novel asthma biomarkers, including molecular and epigenetic ones, shining new light on pathogenesis, phenotyping, and customized therapy in various airway inflammatory patterns of the disease. In addition, research articles on airway epithelial cell dysfunction, airway remodeling, and the overlap between asthma and chronic obstructive pulmonary disease are welcomed. Stanislawa Bazan-Socha (Guest Editors) | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine and Nursing |2 bicssc | |
653 | |a 12-LO | ||
653 | |a airway epithelium | ||
653 | |a airway inflammation | ||
653 | |a airway remodeling | ||
653 | |a allergen immunotherapy | ||
653 | |a allergic inflammation | ||
653 | |a allergic rhinitis | ||
653 | |a allergy | ||
653 | |a anti-inflammatory | ||
653 | |a asthma | ||
653 | |a Bcl10 | ||
653 | |a biomarkers | ||
653 | |a BLT2 | ||
653 | |a bronchial asthma | ||
653 | |a bronchial epithelial cells | ||
653 | |a bronchial fibroblasts | ||
653 | |a Candida albicans | ||
653 | |a CBA assay | ||
653 | |a cellular compartmentalization | ||
653 | |a children | ||
653 | |a component-resolved diagnosis | ||
653 | |a cytokines | ||
653 | |a diagnosis | ||
653 | |a efficacy | ||
653 | |a eosinophils | ||
653 | |a exacerbation | ||
653 | |a exhaled breath condensate | ||
653 | |a extracellular vesicles | ||
653 | |a factors | ||
653 | |a fibrosis | ||
653 | |a fungal sensitization | ||
653 | |a G-CSF | ||
653 | |a IL-17A | ||
653 | |a immune health | ||
653 | |a investigational | ||
653 | |a mediation effect | ||
653 | |a miRNA | ||
653 | |a miRNAs | ||
653 | |a n/a | ||
653 | |a natural therapeutics | ||
653 | |a neutrophil | ||
653 | |a NF-κB pathway | ||
653 | |a oxidative stress | ||
653 | |a Phase I | ||
653 | |a Phase II | ||
653 | |a proinflammatory | ||
653 | |a prostacyclin | ||
653 | |a RCT | ||
653 | |a serum | ||
653 | |a severe asthma | ||
653 | |a sublingual immunotherapy | ||
793 | 0 | |a DOAB Library. | |
856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/101322 |7 0 |z Open Access: DOAB: description of the publication |
856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/7416 |7 0 |z Open Access: DOAB, download the publication |